References
1- Warren R, Lyu H, Klinkhammer K, De Langhe SPJ. Hippo signaling
impairs alveolar epithelial regeneration in pulmonary
fibrosis[published online ahead of print, 2023 May 11]. Elife.
2023;12:e85092. doi:10.7554/eLife.85092.
2 - Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF
and FGF signalling attenuates fibrosis. Eur Respir J 2007;29:976-985
3-Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Anti-fibrotic
and anti-inflammatory activity of the tyrosine kinase inhibitor
nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther
2014;349:209-220
4-Mann J, Goh NSL, Holland AE, Khor YH. Cough in IdiopathicPulmonary
Fibrosis. Front Rehabil Sci. 2021;2:751798. Published 2021 Oct 18.
doi:10.3389/fresc.2021.751798.
5 - Kim HJ, Perlman D, Tomic R. Natural history of idiopathicpulmonary
fibrosis. Respir Med. 2015;109(6):661-670.
doi:10.1016/j.rmed.2015.02.002.
6- Cox IA, Borchers Arriagada N, de Graaff B, et al. Health-related
quality of life of patients with idiopathic pulmonary fibrosis: a
systematic review and meta-analysis. Eur Respir Rev.
2020;29(158):200154. Published 2020 Nov 5.
doi:10.1183/16000617.0154-2020
7 - D. J. Lederer, F. J. Martinez, Idiopathic Pulmonary Fibrosis. N.
Engl. J. Med. 378, 1811–1823
(2018).
8 - Sverzellati N. Highlights of HRCT imaging in IPF. Respiratory
Research. 2013 Apr;14(1):1-5.
9- Hochhegger B, Marchiori E, Zanon M, Rubin AS, Fragomeni R, Altmayer
S, Carvalho CR, Baldi BG. Imaging in idiopathic pulmonary fibrosis:
diagnosis and mimics. Clinics. 2019 Feb 4;74.
10 - Aiello M, Bertorelli G, Bocchino M, et al. The earlier, the better:
Impact of early diagnosis on clinical outcome in idiopathic pulmonary
fibrosis. Pulm Pharmacol Ther. 2017;44:7-15.
doi:10.1016/j.pupt.2017.02.005.
11 - Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN.
Dietary intake of pirfenidone ameliorates bleomycin-induced lung
fibrosis in hamsters. J Lab Clin Med. 1995;125(6):779-785.
12 - Aimo A, Cerbai E, Bartolucci G, et al. Pirfenidone is a
cardioprotective drug: Mechanisms of action and preclinical evidence.
Pharmacol Res. 2020;155:104694. doi:10.1016/j.phrs.2020.104694
13 - Aimo A, Spitaleri G, Nieri D, Tavanti LM, Meschi C, Panichella
G,Lupón J, Pistelli F, Carrozzi L, Bayes-Genis A, Emdin M. Pirfenidone
for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail Rev. 2022 Apr
14;8:e12. doi: 10.15420/cfr.2021.30. PMID: 35516794; PMCID:
PMC9062707.
14 - Graziani F, Varone F, Crea F, Richeldi L. Treating heart failure
with preserved ejection fraction: learning from pulmonary fibrosis. Eur
JHeart Fail. 2018;20(10):1385-1391. doi:10.1002/ejhf.1286
15 - Hara H, Takeda N, Komuro I. Pathophysiology and therapeutic
potential of cardiac fibrosis. Inflamm Regen. 2017;37:13. Published 2017
Jul 17. doi:10.1186/s41232-017-0046-5
16 - Molina-Molina M, Machahua-Huamani C, Vicens-Zygmunt V, et al.
Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF
fibroblasts and human alveolar epithelial cells. BMC Pulm Med.
2018;18(1):63. Published 2018 Apr 27. doi:10.1186/s12890-018-0626-4
17 - Jin J, Togo S, Kadoya K, et al. Pirfenidone attenuates lung
fibrotic fibroblast responses to transforming growth factor-β1. Respir
Res. 2019;20(1):119. Published 2019 Jun 11.
doi:10.1186/s12931-019-1093-z
18 - Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M.
Inflammation and immunity in IPF pathogenesis and treatment. Respir Med.
2019;147:79-91. doi:10.1016/j.rmed.2018.12.015
19 - Hirano A, Kanehiro A, Ono K, et al. Pirfenidone modulates airway
responsiveness, inflammation, and remodeling after repeated challenge.
Am J Respir Cell Mol Biol. 2006;35(3):366-377.
doi:10.1165/rcmb.2005-0452OC
20 - Ali MF, Egan AM, Shaughnessy GF, et al. Antifibrotics Modify
B-Cell-induced Fibroblast Migration and Activation in Patients with
Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol.
2021;64(6):722-733. doi:10.1165/rcmb.2020-0387OC
21 - Zang C, Zheng Y, Wang Y, Li L. The effects and safety of
pirfenidone in the treatment of idiopathic pulmonary fibrosis:
ameta-analysis and systematic review. Eur J Med Res. 2021;26(1):129.
Published 2021 Oct 30. doi:10.1186/s40001-021-00601-y
22 - Kang J, Chung MP, Park MS, Oh IJ, Lee HB, Kim YW, Park JS, Uh
ST,Kim YS, Jegal Y, Song JW. Clinical outcomes of dose modification
during pirfenidone treatment for IPF: A nationwide post-marketing
surveillance study. Front Pharmacol. 2023 Jan 10;13:1025947.
doi:10.3389/fphar.2022.1025947. PMID: 36703754; PMCID: PMC9871582.
23 - L. Wollin, E. Wex, A. Pautsch, G. Schnapp, K.E. Hostettler, S.
Stowasser, et al.,Mode of action of nintedanib in the treatment of
idiopathic pulmonary fibrosis,Eur. Respir. J. 45 (5) (2015) 1434–1445.
24 - Wollin L, Ostermann A, Williams C. Nintedanib inhibits pro-fibrotic
mediators from T cells with relevance to connective tissue
disease-associated interstitial lung disease.
25 - McCormack PL. Nintedanib: first global approval. Drugs.
2015;75(1):129-139. doi:10.1007/s40265-014-0335-0
26 - Ley B. Clarity on Endpoints for Clinical Trials in Idiopathic
Pulmonary Fibrosis. Ann Am Thorac Soc. 2017;14(9):1383-1384.
doi:10.1513/AnnalsATS.201706-423ED
27 - Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U,et
al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
N Engl J Med. 2014;370:2071–82.
28 - Kolb M, Raghu G, Wells AU, Behr J, Richeldi L, Schinzel B, et al.
Nintedanib plus sildenafil in patients with idiopathic pulmonary
fibrosis. N Engl J Med. 2018;379:1722–31
29 - Schmid U, Weber B, Magnusson MO, Freiwald M. Exposure-efficacy
analyses of nintedanib in patients with chronic fibrosing interstitial
lung disease. Respir Med. 2021;180:106369.
doi:10.1016/j.rmed.2021.106369
30 - Lamb YN. Nintedanib: A Review in Fibrotic Interstitial LungDiseases
[published correction appears in Drugs. 2021 Apr 13;:][published
correction appears in Drugs. 2021 Jun;81(9):1133]. Drugs.
2021;81(5):575-586. doi:10.1007/s40265-021-01487-0
31 - Marzin K, Kretschmar G, Luedtke D, et al. Pharmacokinetics of
Nintedanib in Subjects With Hepatic Impairment. J Clin Pharmacol.
2018;58(3):357-363. doi:10.1002/jcph.1025
32 - Ahangari F, Becker C, Foster DG, et al. Saracatinib, a Selective
Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of
Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022;206(12):1463-1479.
doi:10.1164/rccm.202010-3832OC
33 - Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of
tissue remodeling and fibrosis and its inhibition can reverse the
process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.
Published 2012 Jun 6. doi:10.1186/1755-1536-5-S1-S24
34 - Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an
anti-connective tissue growth factor therapy, for idiopathic pulmonary
fibrosis (PRAISE): a phase 2, randomised, double-blind
,placebo-controlled trial. Lancet Respir Med. 2020;8(1):25-33.
doi:10.1016/S2213-2600(19)30262-0
35 - Wells A.U. Pamrevlumab in idiopathic pulmonary fibrosis. Lancet
Respir. Med. 2020;8:2–3. doi: 10.1016/S2213-2600(19)30339-X.
36 - Sgalla G., Franciosa C., Simonetti J., Richeldi L. Pamrevlumab for
the treatment of idiopathic pulmonary fibrosis. Expert Opin. Investig.
Drugs. 2020;29:771–777. doi: 10.1080/13543784.2020.1773790.
37 - Raghu G, van den Blink B, Hamblin MJ, et al. Effect of Recombinant
Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in
Patients With Idiopathic Pulmonary Fibrosis: A
Randomized Clinical Trial. JAMA. 2018;319(22):2299-2307.
doi:10.1001/jama.2018.6129
38 - Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical
trials over the past 25 years. Eur Respir J. 2017;50(4):1701209.
Published 2017 Oct 26. doi:10.1183/13993003.01209-2017
39 - Raghu G, Hamblin MJ, Brown AW, et al. Long-term evaluation of the
safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in
patients with idiopathic pulmonary fibrosis (IPF): an open-label
extension study. Respir Res. 2022;23(1):129. Published 2022 May 21.
doi:10.1186/s12931-022-02047-0
40 - Richeldi L, Azuma A, Cottin V, et al. Plain language summary:
Clinical study of BI 1015550 as a potential treatment for idiopathic
pulmonary fibrosis [published online ahead of print, 2022 Dec 20].
JComp Eff Res. 2022;10.2217/cer-2022-0142. doi:10.2217/cer-2022-0142
41 - Maher TM, Kreuter M, Lederer DJ, et al. Rationale, design and
objectives of two phase III, randomised, placebo-controlled studies of
GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis
(ISABELA 1 and 2). BMJ Open Respir Res. 2019;6(1):e000422. Published
2019 May 21. doi:10.1136/bmjresp-2019-000422
42 - Van Der Aar EM, Fagard L, Desrivot J, et al. Favorable human
safety, pharmacokinetics and pharmacodynamics of the autotaxin inhibitor
GLPG1690, a potential new treatment in idiopathic
pulmonary fibrosis. Am J Respir Crit Care Med.2016;193:A2701.
43 - Heckmann B, Blanque R, Triballeau N, et al. Autotaxin inhibitors in
IPF. Am J Respir Crit Care Med.2019;199:A2585.
44 - Maher TM, van der Aar EM, Van de Steen O, et al. Safety,
tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a
novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis
(FLORA). Lancet Respir Med. 2018;6(8):627-635.
45 - Maher TM, Ford P, Brown KK, et al. Ziritaxestat, a Novel Autotaxin
Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The
ISABELA 1 and 2 Randomized Clinical Trials. JAMA.
2023;329(18):1567-1578. doi:10.1001/jama.2023.5355
46 - GillMW, Murphy BJ, Cheng PTW, et al. Mechanism of hepatobiliary
toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic
pulmonary fibrosis. Toxicol Appl Pharmacol. 2022;438:115885.
47 - Zulfikar S, Mulholland S, Adamali H, Barratt SL. Inhibitors of the
autotaxin-lysophosphatidic acid axis and their potential in the
treatment of interstitial lung disease. Clin Pharmacol. 2020;12:97-108.
48 - Gagnon L, Leduc M, Thibodeau JF, et al. A Newly Discovered
Antifibrotic Pathway Regulated by Two Fatty Acid Receptors: GPR40 and
GPR84. Am J Pathol. 2018;188(5):1132-1148.
doi:10.1016/j.ajpath.2018.01.009
49 - Khalil N, Manganas H, Ryerson CJ, et al. Phase 2 clinical trial of
PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J.
2019;53(3):1800663. Published 2019 Mar 18.
doi:10.1183/13993003.00663-2018
50 - Decaris ML, Schaub JR, Chen C, et al. Dual inhibition of αvβ6 and
αvβ1 reduces fibrogenesis in lung tissue explants from patients with
IPF. Respir Res. 2021;22(1):265. Published 2021 Oct 19.
doi:10.1186/s12931-021-01863-0
51 -Theraputics, P. Pliant Therapeutics Announces Positive Safety and
Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in
Patients with Idiopathic Pulmonary Fibrosis. Available
online:https://ir.pliantrx.com/node/7886/pdf (accessed on 6 February
2023).
52 - Palmer SM, Snyder L, Todd JL, et al. Randomized,
Double-Blind,Placebo-Controlled, Phase 2 Trial of BMS-986020, a
Lysophosphatidic acid Receptor Antagonist for the Treatment of
Idiopathic Pulmonary Fibrosis. Chest. 2018;154(5):1061-1069.
doi:10.1016/j.chest.2018.08.1058
53 - Gill MW, Lakshmi S, Cheng PT, Murphy BJ, Chadwick K,
Lehman-McKeeman L, Graziano M. BMS-986278, an LPA1 receptor antagonist
for idiopathic pulmonary fibrosis: preclinical assessments of potential
hepatobiliary toxicity. InD17. TOWARDS THE NEXT IPF
THERAPIES 2019 May (pp. A5882-A5882). American Thoracic Society.
54 - Tirucherai GS, Yu D, Revankar R. BMS-986278, A lysophosphatidic
acid 1 (LPA1) receptor antagonist, in healthy participants: a
single/multiple ascending dose (SAD/MAD) and Japanese MAD (JMAD) phase 1
study. Am J Respir Crit Care Med 2020;201:A1492.
55 - Nishi Y, Sano H, Kawashima T, et al.Role of galectin-3 in human
pulmonary fibrosis. Allergol Int 2007; 56: 57–65.
doi:10.2332/allergolint.O-06-449
56 - Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of
transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J
Respir Crit Care Med. 2012;185(5):537-546.
doi:10.1164/rccm.201106-0965OC
57 - Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3
expression and secretion links macrophages to the promotion of renal
fibrosis. Am J Pathol. 2008;172(2):288-298.
doi:10.2353/ajpath.2008.070726
58 - MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of
alternative macrophage activation by galectin-3. J Immunol 2008; 180:
2650–2658. doi:10.4049/jimmunol.180.4.2650
59 - Hirani N, MacKinnon AC, Nicol L, et al. Target inhibition of
galectin-3 by inhaled TD139 in patients with idiopathic pulmonary
fibrosis [published correction appears in Eur Respir J. 2022
Apr14;59(4):]. Eur Respir J. 2021;57(5):2002559. Published 2021 May
27. doi:10.1183/13993003.02559-2020
60 - Kellogg DL, Kellogg DL Jr, Musi N, Nambiar AM. Cellular Senescence
in Idiopathic Pulmonary Fibrosis. Curr Mol Biol Rep. 2021;7(3):31-40.
doi:10.1007/s40610-021-00145-4.
61 - Tchkonia T, Palmer AK, Kirkland JL. New Horizons: Novel Approaches
to Enhance Healthspan Through Targeting Cellular Senescence and Related
Aging Mechanisms. J Clin Endocrinol Metab. 2021;106(3):e1481-e1487.
doi:10.1210/clinem/dgaa728.
62 - Zhu Y, Tchkonia T, Pirtskhalava T, et al. The Achilles’ heel of
senescent cells: from transcriptome to senolytic drugs. Aging Cell.
2015;14(4):644-658. doi:10.1111/acel.12344.
63 - Malavolta M, Pierpaoli E, Giacconi R, et al. Pleiotropic Effects of
Tocotrienols and Quercetin on Cellular Senescence: Introducing the
Perspective of Senolytic Effects of Phytochemicals. Curr Drug Targets.
2016;17(4):447-459. doi:10.2174/1389450116666150907105104.
64 - Reyes-Farias M, Carrasco-Pozo C. The Anti-Cancer Effect of
Quercetin: Molecular Implications in Cancer Metabolism. Int J Mol Sci.
2019;20(13):3177.
65 - Zhu Y, Doornebal EJ, Pirtskhalava T, et al. New agents that target
senescent cells: the flavone, fisetin, and the BCL-XL inhibitors,
A1331852 and A1155463. Aging (Albany NY). 2017;9(3):955-963.
doi:10.18632/aging.101202.
66 - Kreuter M, Polke M, Walsh SLF, et al. Acute exacerbation of
idiopathic pulmonary fibrosis: international survey and call for
harmonisation. Eur Respir J. 2020;55(4):1901760. Published 2020 Apr3.
doi:10.1183/13993003.01760-2019.
67 - Jang HJ, Yong SH, Leem AY, et al. Corticosteroid responsiveness in
patients with acute exacerbation of interstitial lung disease admitted
to the emergency department. Sci Rep. 2021;11(1):5762. Published 2021
Mar 11. doi:10.1038/s41598-021-85539-.
68 - Papiris SA, Kagouridis K, Kolilekas L, et al. Survival in
Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid
approach. BMC Pulm Med. 2015;15:162. Published 2015 Dec 14.
doi:10.1186/s12890-015-0146-4
69 - Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of
idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J.
2015;46(2):512-520. doi:10.1183/13993003.00419-2015. 73 - Hyldgaard C,
Hilberg O, Bendstrup E. How does comorbidity influence survival in
idiopathic pulmonary fibrosis?. Respiratory medicine. 2014 Apr
1;108(4):647-53.
70 - Hyldgaard C, Hilberg O, Bendstrup E. How does comorbidity influence
survival in idiopathic pulmonary fibrosis?. Respiratory medicine. 2014
Apr 1;108(4):647-53.
71 - Idiopathic Pulmonary Fibrosis Clinical Research Network.
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
New England Journal of Medicine. 2012 May 24;366(21):1968-77.
72 - Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary
Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An
Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit
Care Med. 2022;205(9):e18-e47. doi:10.1164/rccm.202202-0399ST.
73 - Yung LM, Yang P, Joshi S, et al. ACTRIIA-Fc rebalances activin/GDF
versus BMP signaling in pulmonary hypertension. Sci Transl Med.
2020;12(543):eaaz5660. doi:10.1126/scitranslmed.aaz566
74 - Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the
Treatment of Pulmonary Arterial Hypertension. N Engl J Med.
2021;384(13):1204-1215. doi:10.1056/NEJMoa2024277
75 - ClinicalTrials.gov. A Study of Sotatercept for the Treatment of
Pulmonary Arterial Hypertension (SPECTRA). Date last accessed: 16
December 2021. https://clinicaltrials.gov/ct2/show/NCT03738150
76 -Waxman AB, Risbano MG, Frantz RP, Manimaran S, Lu J, Rischard F. The
SPECTRA study: A phase 2a single-arm, open-label, multicenter
exploratory study to assess the effects of sotatercept for the treatment
of pulmonary arterial hypertension (PAH). In: D3. D003 COME TOGETHER -
CLINICAL ADVANCES IN PULMONARY HYPERTENSION: LESSONS FROM BEST
ABSTRACTS. American Thoracic Society; 2021.